Sep 21, 2020, 7:52 AM
“We are excited to add our collaborator Dr. Robert Bowser to our advisory board. Bob is a worldwide leader in ALS biomarker development. His expertise will be critical as we look to validate key, CNS-specific, mechanistic biomarkers for our PIKFYVE programs,” said Sam Alworth, co-founder and chief executive officer of AcuraStem.
AcuraStem Partners with Team Nanci and The ALS Association Golden West Chapter at LA Walk to Defeat ALS
Nov 7, 2019, 12:08 AM
AcuraStem was honored to once again partner with Team Nanci and the ALS Association Golden West Chapter in the fight against ALS as a sponsor of the 17th Annual Los Angeles County Walk to Defeat ALS® on Sunday, November 3, at Exposition Park in Los Angeles.
AcuraStem Triggers $3M Phase II Fast Track SBIR Grant to Accelerate Preclinical Development of its AS-1 Program for ALS
Oct 22, 2019, 6:47 PM
AcuraStem announced today that the company has triggered Phase II funding worth $3 million from its Fast Track Small Business Innovation Research (SBIR) grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH).
Jan 15, 2019, 11:20 AM
MDA has awarded an MVP grant totaling $300,000 over two years to AcuraStem to support preclinical development of a novel small molecule therapeutic for ALS.
CMTRF Inks Milestone-Driven Partnership with AcuraStem to Repurpose Established Drugs for the Treatment of Charcot-Marie-Tooth Disease
Dec 20, 2018, 10:38 AM
CMT Research Foundation announced today it has entered into a collaborative research partnership with AcuraStem to test thousands of compounds aimed at producing effective treatments for Charcot-Marie-Tooth disease.
AcuraStem Joins Team Nanci and The ALS Association Golden West Chapter at LA Walk to Defeat ALS Sunday, Nov. 4
Nov 2, 2018, 11:59 PM
AcuraStem will join in the fight against ALS as a sponsor of the 16th Annual Los Angeles County Walk to Defeat ALS® on Sunday, November 4, at Exposition Park in Los Angeles. The team will walk with “Team Nanci” and be on hand at the AcuraStem booth to talk to patients and families affected by Amyotrophic Lateral Sclerosis (ALS) about its mission and research underway.
Aug 30, 2018, 7:24 PM
AcuraStem has announced the members of its Scientific Board of Advisors comprised of PhDs, professors, tech entrepreneurs, and successful drug company veterans.
Jul 27, 2018, 4:16 PM
AcuraStem announces the addition of Monica Zhou, Ph.D. to their team as Principal Scientist. Zhou is in charge of industrializing the expansion of AcuraStem’s groundbreaking iNeuroRx platform and its multiple applications, ensuring their accuracy and efficiency.
AcuraStem Receives Fast-Track SBIR Grant for the Development of a Novel Small Molecule Therapy to Treat ALS
Jun 18, 2018, 7:00 AM
AcuraStem a fast-growing and innovative biotech company located in Monrovia, California, has been awarded a $3.7 million Small Business Innovation Research (SBIR) Fast-Track grant (#R44NS105156) by the National Institute of Neurological Disorders and Stroke (NINDS) to continue research for the development of a small molecule therapeutic, “AS2015”, focused on treating patients with the genetic form of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) caused by expansion repeats in the gene C9ORF72.
May 22, 2018, 9:36 PM
AcuraStem is pleased to announce that it has been selected as a finalist in the 2018 Start-Up Stadium event at the BIO International Convention, June 4-7 in Boston.